1 mL/min) and who received a single intravenous infusion of metronidazole 500 mg had no significant change in metronidazole pharmacokinetics but had 2-fold higher Cmax of hydroxy-metronidazole and 5-fold higher Cmax of Metronidazole is the drug of choice for amebiases, vaginal trichomonasis and trichlomonadic urethritis in men, lambliosis, amebic dysentery, and anaerobic infections caused by microorganisms that are sensitive to the drug
The usual adult oral dosage is 7
Inhibitions CYP 3A4 (responsible for metabolism of 50% of drugs) Potentiates effect of warfarin
FLAGYL (metronidazole) capsules, 375 mg, (indicated below as FLAGYL 375 capsules) contain 375 mg of metronidazole USP
FLAGYL (metronidazole) tablets contain 250 mg or 500 mg of metronidazole
Metronidazole is an antibiotic that may be used to treat certain infections of the vagina, stomach, liver, skin, joints, brain and spinal cord, lungs, heart, or
Renal Impairment
In the treatment of most serious anaerobic infections, intravenous metronidazole is usually administered initially
Peripheral neuropathy with prolonged use
FLAGYL (metronidazole) tablets, 250 mg or 500 mg is an oral formulation of the synthetic nitroimidazole antimicrobial What is the use of Flagyl 200mg 400mg 500mg? - Flagyl has been used successfully in: septicaemia, bacteraemia, brain abscess, necrotising pneumonia, osteomyelitis, puerperal sepsis, pelvic abscess, pelvic cellulitis
10
More recently, metronidazole
Selecting an antibiotic that will optimally treat an infection while minimizing adverse effects and the development of resistance is only the first step, as one must also consider the patient’s individual pharmacokinetic alterations and the pharmacodynamic Lesson on the antibiotic Metronidazole (Flagyl)
Flagyl® Oral Formulation Overdosage (metronidazole oral formulation) Flagyl® Oral Formulation Clinical Pharmacology (metronidazole oral formulation) Flagyl® Oral Formulation (metronidazole oral formulation) medication page for healthcare professionals to search
Solubility Hydrophilic Lipophilic Vol
The 5-nitro group of Metronidazole is reduced by anaerobes metabolically
5 mg/kg every six hours, the average peak steady-state concentrations (Cmax) and trough (Cmin) were 25 mcg/mL and 18 mcg/mL, respectively
The hydroxy metabolite has biological activity of 30 to 65% and a longer elimination half-life than the parent compound
Metronidazole is a synthetic antibacterial and antiprotozoal agent that belongs to the nitroimidazole class
After an oral dose the peak serum concentration is reached approximately